Skip to main content
. 2018 Apr 2;18:34. doi: 10.1186/s12871-018-0497-5

Table 2.

Comparison between survivors and non-survivors in patients with ARDS

Survivors Non-survivors p value
(n = 16) (n = 5)
Clinical data
 Age (year) 59.5 (41.8–70.0) 71.0 (59.5–77.5) 0.136
 Body height (cm) 167 (163–170) 166 (154–170) 0.835
 Body weight (kg) 64 (59–71) 62 (57–80) 0.773
 ALI score 13 (10–14) 13 (12–15) 0.557
 APACHE II 14 (10–19) 18 (14–29) 0.185
Pre-operation
 Hypertension (Yes/No) 2/14 2/3 0.228
 ASA 2 (2–3) 2 (2–3) 0.768
 VATS/open surgery 8/2 4/1 0.660
 Surgery time (minute) 210 (280–457) 320 (220–345) 1.000
 Blood transfusion (Yes/No) 5/5 1/0 0.719
 Airway management 7/3 3/2 0.768
(double-lumen tube/bronchus blocker)
 Anesthesia (volatile/intravenous) 10/0 5/0 1.000
 Intraoperative I/O 780 (1350–1800) 1300 (600–1600) 0.679
 ICU stay days 21 (11–44) 25 (20–43) 0.535
 RASS -1 (−1–0) −2 (−2 - -1) 0.040
 Ventilator free hours 48 (24–68) 0 (0–10) 0.177
 Re-thoracotomy (Yes/No) 0/16 0/5 1.000
 Re-intubation rate (Yes/No) 5/16 2/0 0.780
 SOFA score 8 (7–10) 7 (7–8) 0.313
 WBC 13.3 (7.7–13.4) 12.9 (11.1–14.0) 0.905
 CRP 21.5 (10.9–22.6) 12.4 (11–19.7) 0.495
Medications
 Midazolam (Yes/No) 15/1 5/0 1.000
 Fentanyl (Yes/No) 16/0 5/0 1.000
 Norepinephrine (Yes/No) 6/10 2/3 1.000
 Dopamine (Yes/No) 2/13 1/4 0.842
Ventilator settings
 FIO2 0.70 (0.56–0.94) 0.65 (0.60–0.93) 0.901
 PEEP (cmH2O) 10.0 (8.5–12.0) 10.2 (9.7–13.5) 0.552
 RR (bpm) 16.5 (15.3–23.0) 26.0 (20.0–27.5) 0.156
 Pinsp (cmH2O) 18.0 (15.3–20.0) 22.0 (20.0–22.5) 0.039
 Tinsp (sec) 0.9 (0.8–1.0) 0.9 (0.8–1.0) 0.548
 VT (ml) 425 (385–545) 390 (305–493) 0.385
 MV (l/min) 8.0 (6.6–10.5) 10.2 (6.9–12.9) 0.363
 Cdyn (ml/cmH2O) 21.6 (18.5–32.0) 19.0 (13.9–23.4) 0.231
Arterial gas analysis
 pH 7.42 (7.38–7.45) 7.47 (7.42–7.49) 0.074
 PaO2 (mmHg) 78 (67–97) 90 (66–103) 0.772
 PaCO2 (mmHg) 38 (29–41) 40 (39–51) 0.043
 HCO3 (mmol/l) 24 (19–27) 30 (28–33) 0.003
 PaO2/FIO2 (mmHg) 115 (84–180) 106 (83–171) 0.901
 AaDO2 (mmHg) 384 (256–536) 352 (275–516) 0.967
Time domain HRV measures
 mRRI (ms) 569 (496–636) 655 (600–761) 0.063
 SDRR (ms) 28 (23–34) 31 (30–41) 0.063
 CVRR (%) 4.51 (4.47–4.77) 4.98 (4.49–6.03) 0.409
 RMSSD (ms) 27 (23–35) 34 (31–44) 0.052
Frequency domain HRV measures
 TP (ms2) 161 (113–246) 274 (234–529) 0.023
 VLFP (ms2) 13 (9–55) 22 (20–70) 0.231
 LFP (ms2) 47 (32–59) 75 (64–127) 0.023
 HFP (ms2) 101 (71–133) 175 (148–335) 0.012
 HFP/VT (ms2/ml) 0.23 (0.18–0.32) 0.64 (0.35–0.82) 0.007
 nVLFP (nu) 9.7 (7.9–14.3) 8.9 (6.3–14.4) 0.710
 nLFP (nu) 27.9 (26.9–28.8) 27.4 (22.4–28.3) 0.509
 nHFP (nu) 62.0 (59.4–63.5) 63.7 (57.5–71.0) 0.127
 nHFP/VT (nu/ml) 0.15 (0.10–0.16) 0.17 (0.12–0.24) 0.386
 LHR 0.45 (0.44–0.48) 0.43 (0.33–0.50) 0.127
 LHR*VT (1/ml) 189 (179–254) 161 (95–238) 0.302

Data are presented as medians (25% - 75% interquartile). ALI: acute lung injury score; RASS: Richmond Agitation-Sedation Scale; RASS: Richmond Agitation-Sedation Scale; SOFA: Sequential Organ Failure Assessment; WBC: white blood cells; CRP: C-reactive protein. Other abbreviations are the same as those depicted in Table 1. The "*" in "LHR*VT" denotes multiplication